文献速递药物不良反应与药物警戒

奥贝胆酸药物警戒:FDA不良事件报告系统数据库分析

Pharmacovigilance of obeticholic acid: An analysis of the Food and Drug Administration Adverse Event Reporting System database.
PubMed 文献 · Br J Clin Pharmacol · 2025-08-07

本研究基于FAERS数据库2016年第二季度至2025年第一季度数据,采用4种不成比例分析算法评估奥贝胆酸相关不良事件风险信号。在14 859 866份报告中识别出6177份以奥贝胆酸为主要可疑药物的报告,发现187个显著不成比例首选术语,主要集中于胃肠、肝胆及皮肤皮下组织疾病,并观察到说明书未收录的不良反应如食管静脉曲张和肝纤维化。

要点

  • 奥贝胆酸相关不良事件主要集中在胃肠、肝胆及皮肤皮下组织疾病。
  • 发现说明书未收录信号如食管静脉曲张(ROR 58.39)和肝纤维化(ROR 74.95)。
  • 多数不良事件发生于用药30天内或1年后,女性更频繁,建议监测不少于1年。

核心结论

  • 真实世界研究识别了奥贝胆酸相关不良事件,尤其包括药品说明书未记录的反应,并揭示用药1年后的迟发不良事件。
  • 建议对患者用药安全进行主动监测,监测时长不少于1年。

研究设计与样本

  • 基于FAERS数据库2016年第二季度至2025年第一季度的数据提取分析。
  • 从14 859 866份报告中识别出6177份以奥贝胆酸为主要可疑药物的不良事件报告。
  • 采用报告比值比(ROR)、比例报告比值比、贝叶斯置信传播神经网络和经验贝叶斯几何均值4种算法进行不成比例分析。

主要发现

  • 在27个器官系统中识别出187个显著不成比例的首选术语。
  • 不良事件主要集中于胃肠、肝胆、皮肤和皮下组织疾病。
  • 观察到说明书未列出的不良反应如食管静脉曲张(ROR 58.39 [95%CI 43.67-78.08])和肝纤维化(ROR 74.95 [95%CI 58.59-95.88])。
  • 多数不良事件发生在用药30天内或1年后,女性患者更频繁。

临床怎么用

  • 临床应主动监测奥贝胆酸用药患者的安全性,监测时长不少于1年。
  • 关注胃肠、肝胆及皮肤皮下组织相关不良事件,以及食管静脉曲张和肝纤维化等未收录信号。
  • 对女性患者及用药30天内或1年后的时间段加强不良事件观察。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Obeticholic acid (OCA) is a farnesoid X nuclear receptor agonist that was approved by the Food and Drug Administration in 2016 for the treatment of primary biliary cholangitis. The aim of this study was to investigate the adverse events (AEs) associated with OCA. METHODS: We extracted data from the Food and Drug Administration Adverse Event Reporting System (FAERS) database from the second quarter of 2016 to the first quarter of 2025. Disproportionality analyses were conducted to assess risk signals of AEs associated with OCA through 4 algorithms, encompassing reporting odds ratio (ROR), proportional reporting ratio, Bayesian confidence propagation neural network and empirical Bayesian geometric mean. RESULTS: Out of 14 859 866 reports from the FAERS database, 6177 reports with OCA as principal suspect AEs were identified. Across 27 organ systems, we identified 187 significant disproportionate preferred terms, which mainly concentrated on gastrointestinal, hepatobiliary, skin and subcutaneous tissue disorders. We also observed unlisted adverse reactions, such as oesophageal varices (ROR 58.39 [95% confidence interval 43.67-78.08]) and hepatic fibrosis (ROR 74.95 [95% confidence interval 58.59-95.88]). Most AEs occurred within 30 days or after 1 year of medication, and were more frequent in female patients. CONCLUSION: This real-world study identified OCA-associated AEs, especially some not recorded in the drug insert, and revealed delayed AEs beyond 1 year. These findings highlight the importance of active monitoring for patient medication safety, and we recommend that the monitoring duration be no less than 1 year.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. He Q, Jiang M, Wang Y, et al. Pharmacovigilance of obeticholic acid: An analysis of the Food and Drug Administration Adverse Event Reporting System database. Br J Clin Pharmacol. 2025. PMID: 40776461. doi:10.1002/bcp.70186

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。